Expert insight 29 Aug 2017

Beware of doomsday scenarios for health care spending

Fair pricing activists applauded the news earlier this month that the FDA approved another drug to cure hepatitis C. That this new medicine is cheaper and treats people quicker than the existing hepatitis C drugs goes to show how fast healthy competition can change the outlook on health spending. Not long ago, health economists were promoting a...

Read more
Expert insight 22 Aug 2017

Africa’s population: Failure is not an option

We are used to social media exploding and controversy over statements made by President Donald Trump. But over the past month, a shockwave of anger and charges of European arrogance and racism have been levelled at France’s new, charming, and youthful President.  What triggered the social media storm that spread around the world was President...

Read more
Position paper 13 Jun 2017

IFPMA Position on Convergence of Good Manufacturing Practice (GMP) standards and Related Inspections

This position paper reiterates the global industry position on GMP convergence (June 2017 position paper and addresses the ICDRA WHO recommendations to industry with regard to the sharing of inspections information amongst regulators and procurement agencies under the Reliance approach.

Read more
Statement 6 Jun 2017

IFPMA Statement to New Essential Medicines List

Geneva, 6 June 2017|Today, the WHO issued its 20th Essential Medicines List (EML) This List serves as a guide for countries and procurement agencies in making their own decisions about the medicines in their own formularies. IFPMA Director General Thomas Cueni gave this statement: “In this year’s List, and from what we can notably see,...

Read more
Expert insight 6 Jun 2017

Behind the Numbers: Pharma and Global Health

The most indisputable of all facts on global health is that we’re living longer and healthier lives than ever, and in an era of continuous health improvement. What were once considered life-threatening diseases are now manageable conditions, and not just for patients, but for our health systems also. Where Hepatitis C, for example, would have...

Read more
Infographic 2 Jun 2017

Fight the Fakes Infographic – Same Packaging, Same Shape and Same Color… But Fakes! (Spanish Version)

Read more
Expert insight 2 Jun 2017

Unlikely bedfellows join to fight superbugs

In January 2016, more than 100 companies and industry associations had signed a Declaration on Combatting Antimicrobial Resistance at the World Economic Forum in Davos, followed by a Roadmap of several big pharma at the UN High-Level Meeting in September 2016 – a common framework of principles for global measures to curb the development of antibiotic resistance. The “AMR Industry Alliance” now...

Read more
Press release 31 May 2017

IFPMA contribution to key global health discussions @WHA70 (22-31 May 2017)

Geneva, 31 May 2017 – Starting with the election of Dr Tedros Adhanom Ghebreyesus as Director-General of the World Health Organization (WHO), deliberations during the 70th World Health Assembly (WHA70) in Geneva this week touched upon key public health and global security issues such as cancer prevention and control, antimicrobial resistance, pandemic influenza preparedness, falsified...

Read more
Statement 30 May 2017

WHO WHA 70 agenda item 15.6 Cancer prevention and control in the context of an integrated approach

Delivered by Fumie Griego, Assistant Director General The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) welcomes the resolution and its integrated approach to cancer prevention and control. The economic impact of cancer continues to rise, while the funding to support these efforts have not kept pace. All sectors must come together to ensure that high quality...

Read more
Statement 29 May 2017

WHO WHA 70 agenda item 15.2 Draft global action plan on the public health response to dementia

Delivered by Vanessa Peberdy, Manager, Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for the opportunity to provide our perspective on dementia. IFPMA represents leading research-based pharmaceutical companies, as well as national and regional industry associations worldwide. IFPMA commends the WHO Secretariat for its vision and...

Read more
Statement 29 May 2017

WHO WHA 70 item 13.6 Member State mechanism on SSFFC

WHA70 agenda item 13.6  Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products Delivered by Cyntia Genolet, Manager, Regulatory and Health Policy Progress toward health improvement will not be achievable without a consistent and constant fight against falsified medicines. Falsified medicines deliberately and deceitfully attempt to pass themselves off as genuine approved medicines. They represent a serious...

Read more
Expert insight 29 May 2017

Life-course vaccination: for today, not tomorrow

Thinking about how to be a healthy older person is like thinking about glaciers crashing into Arctic seas as a result of climate change. Too far away to imagine, and we’ll worry when the effects reach our doorsteps. In reality, the challenge is here today asking all of us, at any age, to look ahead...

Read more